Bringing your ideas to life
In support of implantable technologies as diverse as cardiovascular devices, orthopedic implants, tissue regeneration scaffolds, and wound management systems, we offer you a proven family of resorbable polymers – supported by years of expertise across everything from contract manufacturing to custom synthesis.
When it comes to biomedical and resorbable polymers, our track record stretches back to the 1960s.
Today, our state-of-the-art GMP production, research and QA/QC facilities make us one of the most reliable large-scale (yet independent) partners to the industry.
Our PURASORB® family of resorbable polymers can be produced in batch sizes of 5kg up to over 100kg – across a broad range of different specifications. Our R&D laboratory includes a 2kg scale pilot facility, as well as a variety of equipment dedicated to the development and support of polymer compositions.
But our expertise isn’t limited to manufacturing: We also provide extended analytical services and analytical method development and validation.
Quality Resorbable Polymers for Medical Implant Devices and Controlled Drug Delivery Formulations
We maintain cGMP quality systems compliant with ICHQ7 as the basis of our processes and analytical methods.
A Certificate of Analysis is provided with every batch we produce, showing the analytical data determined in our quality control laboratory (with additional analytical data available on request).
We have ISO-9001:2015 certified, dedicated manufacturing facilities in the U.S. and the Netherlands. All our polymers and monomers are covered with a Device Master File (MAF 1961) and/or Drug Master Files (DMF 21817) & (DMF 31084) filed with the FDA.
Most importantly, we allow customers to see this for themselves: They audit our facilities on a regular basis.
We adhere to ICHQ7 guidelines and our processes and analytical methods are validated accordingly
Product not available in your region
This product is not available in the selected region.
If you want this product in your region, or find a suitable alternative, please contact us,
4/30/2021 7:00 AM
Corbion Q1 2021 Interim Management Statement
Corbion reported organic net sales growth of 9.5%. Total net sales were € 251.5 million
4/23/2021 7:00 AM
Corbion appoints Aurélie Dalbiez as Chief Human Resources Officer
Corbion announces the appointment of Aurélie Dalbiez as Chief Human Resources Officer and member of
4/22/2021 11:25 AM
Corbion approach to lactic acid expansion advances sustainability agenda
Expanding production capacity to meet growing global demand for lactic acid while simultaneously achieving Corbion's
Biopesticides Europe 2021 Conference - POSTPONED - new dates to be decided
Brussels | The Global and European biopesticides market has been growing steadily in recent years. With increasing
Milan, Italy | The world's largest pharmaceutical exhibition, CPhI Worldwide houses six zones representing each stage of the
New York, USA | NYSCC Suppliers’ Day serves as one of the most important events on the industry calendar